TD Cowen Downgrades Aerovate Therapeutics to Hold
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joseph Thome has downgraded Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Hold.

June 18, 2024 | 9:42 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TD Cowen analyst Joseph Thome has downgraded Aerovate Therapeutics from Buy to Hold, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less favorable view on Aerovate Therapeutics' near-term prospects, which could lead to a decline in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100